Monte Rosa Q4 net income $13.4M; Ph1 MRT-6160 >90% VAV1 deg, MRT-2359 CRPC response

Monte Rosa Therapeutics, Inc.

Q4 2024 net income $13.4M vs net loss $33.3M in Q4 2023; collaboration revenue $60.6M from Novartis/Roche deals.
Cash, equivalents, securities $377M as of Dec 31, 2024; expected to fund operations into 2028.
MRT-6160 Phase 1 showed >90% VAV1 degradation, favorable safety; path to Phase 2 with Novartis.
MRT-2359 in CRPC: confirmed partial response (-57%) in 1 of 3 evaluable patients; focus on CRPC moving forward.
MRT-8102 NEK7 degrader on track for IND H1 2025; GLP tox showed >200-fold safety margin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.